The Weekly Litigation News Digest is now live. Subscribe now
Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb) - EP4014976
The patent EP4014976 was granted to Idorsia Pharmaceuticals on Sep 4, 2024. The application was originally filed on Feb 26, 2018 under application number EP21202979A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4014976
- Application Number
- EP21202979A
- Filing Date
- Feb 26, 2018
- Status
- Granted And Under Opposition
- Aug 2, 2024
- Publication Date
- Sep 4, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (10) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents